Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$27,000.00

An In Vitro A549-Derived Lung Cancer Model for Evaluating Combined Ablation and Immunotherapy Strategies

FY 2024-25

Summary
Lung cancer remains the leading cause of cancer deaths worldwide. For many patients, traditional surgery isn't possible because of heart and lung conditions or other health issues. For these patients, promising alternative treatments combine two approaches: ablation, which destroys cancer cells using extreme temperatures, and immunotherapy, which helps the body's own immune system fight the cancer more effectively. However, finding the best way to combine these treatments has been challenging because researchers lacked appropriate laboratory models that could accurately represent both the physical structure and biological features of lung tumors.Our research team is developing an innovative three-dimensional model of lung tumors that will transform how we study and improve these combined treatments. We use a special a hydrogel material that mimics the physical properties of actual lung tumors, and we populate it with the same types of cells found in patient tumors - both cancer cells and the surrounding supportive tissues. What makes our model particularly groundbreaking is that we've included tiny artificial blood vessels that function like natural vessels in tumors allowing a true immune response.This advanced tumor model will allow us to study, for the first time, how different combinations of ablation and immunotherapy work together in a controlled setting. By accurately recreating both the physical structure and biological characteristics of lung tumors, our platform helps us understand exactly how different treatments affect the cancer and influence the immune system's response. This bridges the gap between basic laboratory studies and animal testing, offering a powerful new tool to develop better treatment strategies for patients with inoperable lung cancer.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529619
Name
Sarshoghi Arman
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
An In Vitro A549-Derived Lung Cancer Model for Evaluating Combined Ablation and Immunotherapy Strategies
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Ablation; Cryoablation; Nsclc; Thoracic Oncology
Abstract
Lung cancer remains the leading cause of cancer deaths worldwide. For many patients, traditional surgery isn't possible because of heart and lung conditions or other health issues. For these patients, promising alternative treatments combine two approaches: ablation, which destroys cancer cells using extreme temperatures, and immunotherapy, which helps the body's own immune system fight the cancer more effectively. However, finding the best way to combine these treatments has been challenging because researchers lacked appropriate laboratory models that could accurately represent both the physical structure and biological features of lung tumors.Our research team is developing an innovative three-dimensional model of lung tumors that will transform how we study and improve these combined treatments. We use a special a hydrogel material that mimics the physical properties of actual lung tumors, and we populate it with the same types of cells found in patient tumors - both cancer cells and the surrounding supportive tissues. What makes our model particularly groundbreaking is that we've included tiny artificial blood vessels that function like natural vessels in tumors allowing a true immune response.This advanced tumor model will allow us to study, for the first time, how different combinations of ablation and immunotherapy work together in a controlled setting. By accurately recreating both the physical structure and biological characteristics of lung tumors, our platform helps us understand exactly how different treatments affect the cancer and influence the immune system's response. This bridges the gap between basic laboratory studies and animal testing, offering a powerful new tool to develop better treatment strategies for patients with inoperable lung cancer.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sarshoghi, Arman
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~